Orna Therapeutics (Eli Lilly)
Circular-RNA in vivo CAR company bought by Eli Lilly for about $2.4B in February 2026.
Orna's oRNA (engineered circular RNA) in lipid nanoparticles induces CAR expression in T cells inside the body without lymphodepletion. Lead ORN-252 (CD19) targets autoimmune disease; a BCMA in vivo CAR programme for myeloma is preclinical. Lilly announced the acquisition on 9 February 2026.
Pages like this
not linked directly; found by shared links- CompanyUmoja Biopharma
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, CD19 and the tag frontier.
- CompanyInterius BioTherapeutics
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- CompanyIsomorphic Labs
Shares Eli Lilly (incl. Loxo) and the tag frontier.
- TechnologyCAR-NK & CAR-macrophage
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyTargeted alpha therapy
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyIn vivo base and prime editing for cancer
Shares In vivo CAR-T and the tag frontier.
- TechnologyEngineered exosomes as drug carriers
Shares In vivo CAR-T and the tag frontier.
- TechnologyLogic-gated therapeutics (AND, NOT gates)
Shares In vivo CAR-T and the tag frontier.